KRAS mutation in adenocarcinoma of the gastrointestinal type arising from a mature cystic teratoma of the ovary
© Li et al.; licensee BioMed Central Ltd. 2014
Received: 7 March 2014
Accepted: 25 August 2014
Published: 6 September 2014
Mature cystic teratomas (MCT) in the ovary rarely undergo malignant transformation. Moreover, adenocarcinoma of the gastrointestinal type is much rarer. We present two cases of perimenopausal female pateints with mature cystic teratoma of single ovary, while local adenocarcinoma arising in the MCT. The malignancies showed immunohistochemical features of intestinal differentiation, such as strong positivity for CDX-2, villin and CK-20, and negativity for CK-7. Furthermore, the mutation analysis of molecular alteration revealed a KRAS gene mutation in the intestinal adenocarcinoma part, extending into benign intestinal-type epithelium linings. Yet the mutation was not present in the epidermal component of the teratoma. We present these as two unique cases of mucinous adenocarcinoma of the intestinal type arising from mature cystic teratoma. Moreover, we also submit that this KRAS mutation might contribute to identify malignant transformation of a MCT and suggest possible effect on targeted treatment decisions for anti-epidermal growth factor receptor (EGFR) therapy in metastasized patients.
KeywordsOvary Mature cystic teratoma Malignant transformation Adenocarcinoma Intestinal type KRAS mutation
The most common tumor of ovary is mature cystic teratoma (MCT), which arises from germ cells and accounts for more than 20% of all ovarian tumors . Malignant transformation of MCTs occurs in 1-2% of all these tumors . During the malignancies arising in the MCT, squamous cell carcinoma is the most common type , with adenocarcinomas comprising only 6.8% of the malignant changes ,. Furthermore, adenocarcinomas of the gastrointestinal type are much less frequent. So far there have been few reports of adenocarcinoma of the gastrointestinal type in the ovary arising from an MCT -.
We present two cases with similarity of primary adenocarcinoma of the gastrointestinal type likely arising in a mature cystic teratoma of the ovary. Either patient had no evidence of a primary tumor elsewhere by previous medical history or radiographic survey. After extensive histological examination, the cyst with adenocarcinoma was found in continuity with a benign cystic lesion, which seemed at first slightly thicker compared to the surrounding normal wall. Yet, the microscopic evaluation revealed this part of cyst covered by epithelium showing malignant transformation into carcinoma with clearly defined irregular glands infiltrating into the stroma. The immunohistochemical (IHC) staining of the malignant change showed strong positivity for cytokeratin-20 (CK-20), villin and caudal type homeobox transcription factor 2 (CDX-2), while negative for CK-7. Moreover, as a number of studies had proved Kirsten rat sarcoma viral oncogene homolog (KRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) oncogene mutations are recognized biomarkers that predict lack of response to anti-epidermal growth factor receptor (EGFR) antibody therapies and are associated with a worse prognosis in patients with metastatic adenocarcinoma in colorectal cancer -. To investigate further treatment in case of recurrence and metastasis of intestinal carcinoma for those two patients, we evaluate molecular alteration on oncogene mutation in cysts carrying adenocarcinoma, which showed positive for KRAS mutation and the mutation was extended into the benign intestinal-type epithelium of the cyst.
Thus, we conclude that the adenocarcinoma of intestinal type was likely arising from a mature cystic teratoma. We also submit that this KRAS mutation might be helpful in identifying malignant transformation of a MCT and suggest possible effect on targeted treatment decisions for anti-epidermal growth factor receptor (EGFR) therapy in metastasized patients.
The first patient was a 51-year-old perimenopausal female, gravida 3, para 1, who was admitted with occasional nausea, abdominal pain and bloating for the past few years. Her previous medical, surgical, gynecological, and family histories were all unremarkable, with regular menstrual cycle. A mass in the left adnexal region was found in a routine pelvic examination. Ultrasound scan revealed the presence of an approximately 6 cm complex cystic mass of the left ovary. And there were no abnormal findings of the uterus and right adnexae. The patient had slightly elevated serum level of only one tumor marker. Her carbohydrate atigen 19–9 (CA199) was elevated to 41.9 U/ml (normal < 35 U/ml), while the other serum tumor markers, including carcinoembrionic antigen (CEA), CA 125, α-fetoprotein(AFP), were all within the normal ranges.
An exploratory laparoscopy with frozen section of the left ovarian tumor was performed. After the result of frozen section confirming malignant change in MCT, the procedure was changed to a total hysterosalpingo-oophorectomy with 400 mg intraperitoneal carboplatin. Appendectomy and omentectomy were also carried out. Postoperatively, the patient opted for adjuvant chemotherapy, consisting of 6 cycles of paclitaxel (135 mg/m2) and carboplatin (area under the curve [AUC] of 5). After adjuvant chemotherapy, the patient’s CA199 went back to normal and a whole-body positron emission tomographic scan was performed, the result of which was negative. The patient remains free of disease 13 months following diagnosis.
Macroscopically, the left ovary contained a smooth cystic mass (5.8 cm × 4.5 cm) filling with sebaceous material, hair and teeth. The wall was average 0.1 cm - 0.3 cm thin. Most of the inner surface of the mass was smooth, and had partial thicking-like nodules lining a rough surface. The right ovary was 3.2 cm × 1.2 cm × 1.0 cm and otherwise unremarkable. The cervix contained 1 small mucous cyst, and the uterus contained 2 small leiomyomas (0.8 cm × 1.0 cm diameter).
Previous reports of adenocarcinoma of the gastrointestinal type arising from a MCT of the ovary
Tumor size (cm)
Ueda G et al. 
TAH + BSO
Fishman A et al. 
CEA: 40 ng/ml CA 125: 80 U/ml CA153: 60 U/ml
20 × 13 × 8.5
TAH + BSO + OMT + APT
5 FU Leucovorin
DOD 3 month after surgery
Kushima M 
CA19-9: 109 U/ml SLX: 58.5 U/ml CA125: 36 U/ml CA72-4: 19 U/ml
6.4 × 4.8 × 2.8
Levine DA 
CEA: 11.2 ng/ml CA 125, AFP, HCG: WNR
15 × 12 × 11
Unilateral SO + OMT + PLN + PAN
Guney M 
CA1 25: 99.1 U/ml CA19-9 > 1000 U/ml CEA: WNR
TAH + BSO + OMT + PLN + PAN
Min KJ 
CA125: 72 U/ml
17 × 14 × 2
TAH + BSO
Takai M 
CEA: 6.9 ng/ml CA 125: 20 U/ml CA19-9: 3.8 U/ml SCC: 1.1 ng/ml
6.7 × 5.7
TAH + BSO + OMT
Dov Hershkovitz 
CA-19-9:162 U/ml CEA: 5.5 ng/ml CA-125: 268 U/ml AFP, HCG: WNR
7 × 10
CA19-9: 41.9 U/ml CEA, CA 125, AFP: WNR
5.8 × 4.5
TAH + SO + OMT + APT
P + C
CA199 > 1200 U/ml
10.8 × 9.7
TAH + SO
We present two cases with similarity of primary adenocarcinoma of the gastrointestinal type, harboring KRAS oncogene mutation, likely arising in a mature cystic teratoma of the ovary. As far as we know, these two cases are unique because currently there have been few report on teratoma-associated adenocarcinoma carrying KRAS oncogene mutation ,-,,.
Malignant transformation of MCTs is a rare, often asymptomatic event which most commonly occurs in postmenopausal women. Also there have been plenty of varying reports on that, the risk of malignancy is estimated to be between 0.17 – 2% among all the transformations. As expected, any component of the MCTs might undergo malignant transformation, but most of the time (about 80%) squamous epithelium is the most often prone to undergo malignant changes, which results in the squamous carcinoma . Some less common malignancies include thyroid carcinomas , adenocarcinomas ,-, or, less commonly, carcinoid tumors , mixed thyroid-carcinoid (struma carcinoid) .
The literature establishing adenocarcinoma of the gastrointestinal type is much rarer. To our knowledge, so far there have been only a few reports on it ,,,-,,,. Although Kajo K et al. reported a case about mucinous carcinoma of non-intestinal type arising in the ovarian MCT , yet most of the previously described adenocarcinoma in MCTs showed characteristics of intestinal differentiation with immunohistochemical expression of CDX-2 and CK-20, and with negativity of CK-7 ,. In present study, the immunohistochemical analysis showed positive staining in the CDX-2, CK-20 and villin, while the adenocarcinoma part was negative for CK-7, ER and HER2. The patient also underwent gastrointestinal endoscope to rule out the possibility of metastasis. Therefore, the diagnosis of present cases is adenocarcinoma of the intestinal type arising from a MCT.
The pathogenesis of mucinous adenocarcinoma arising from MCTs is somewhat different from that of colorectal cancer regarding clinical conditions. Morphology and immunophenotype of the intestinal type arising from a MCT are the same as in colorectal adenocarcinoma, more investigations are needed for further understanding pathogenesis particularly using molecular genetic analysis, like detection of mutation status. Although it has been claimed that colorectal adenocarcinoma is genetically similar to an intestinal-type adenocarcinoma in lung , so far there have been few reports on genetic comparison between colorectal adenocarcinoma and mucinous adenocarcinoma arising from MCTs. Reasons for the problem may be due to the limited case number and difficulty in separating the areas between the mucous components and adenocarcinoma part. Interestingly, recent studies on analysis of microsatellite polymorphism in mucinous ovarian carcinomas and associated teratomas showed a clonal match between the samples, suggesting that a subset of mucinous ovarian carcinoma actually arise from mature teratomas . Fujii K et al. also demonstrated that the origin of the intestinal-type mucinous tumors might arise from mature cystic teratomas by microdissection and analysis of microsatellite markers . Related studies gave us a clue to isolate different teratoma components and explore molecular genetic analysis.
It is difficult to make a diagnosis of malignant transformation of a MCT preoperatively. The patient’s age, extremely enlarged mass in adnexal region by imaging and elevated tumor maker might remind the possibility of malignancy. In preset study, both patients were perimenopausal. Not only were the imaging results abnormal, but also the tumor maker CA199 elevated. Yet, extensive histological sampling was still crucial to reveal the carcinoma part, especially for local malignancy. In present cases, mutation analysis of molecular alterations showed a KRAS mutation in both the adenocarcinoma part and benign intestinal-type epithelium of the cyst. KRAS mutations were observed in 43% of ovarian carcinomas and in 30% of colorectal carcinomas, which do not contribute to differential diagnosis in mucinous neoplasms of the colon and ovary . Yet, mutation analysis might contribute to predict the malignant transformation in MCTs in case of under-diagnosis, especially for small lesion of malignancy. Moreover, the absence of KRAS mutation in the mature teratoma element in our samples suggests that this mutation accompanies with the intestinal-type epithelium.
The prognosis of patients with malignant transformation in MCTs is generally poor  and the majority of women die within a year after diagnosis . The top affecting factor is tumor dissemination . Thus, establishing an optimal therapeutic plan is important. So far, the treatment of choice for these tumors is surgery and there is little information on treatment outcomes of patients receiving chemotherapy directed to transformed histology given localized disease at presentation. Unfortunately, with tumors extending beyond the ovary, prognosis seems to be very poor. Dechaphunkul A et al. reported a case that a patient who achieved good response from chemotherapy directed to transformed histology, which confirms the importance of chemotherapy regimen used . It brought us a new strategy of treatment by targeting at transformed histology. KRAS status is presently the only biomarker routinely used to select patients with colon cancer for EGFR inhibition-targeted therapy, which is widely used to treat metastatic colorectal cancer . Thus we speculated if there was any chance for anti-EGFR antibody therapies after failure of first-line therapies, especially for metastasized patients. Further conclusions on selecting anti-EGFR antibody therapies need larger numbers of case studies and molecular genetic analysis in the intestinal-type adenocarcinoma arising from MCTs. Still, a risk and benefit discussion should be had with the patient, keeping in mind her age, comorbidities, surgical, and pathological findings.
Our case represents two unique cases of single ovarian MCT with malignant transformation to gastrolintestinal adenocarcinoma carrying KRAS mutation.
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This work was supported by the National Natural Science Foundation of China (grants 81200104 and 81302020) and Medical Scientific Research Foundation of Hubei Province (grant JX3B07). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Park JH, Whang SO, Song ES, Choi SJ, Lee WY: An ovarian mucinous cystadenocarcinoma arising from mature cystic teratoma with para-aortic lymph node metastasis: a case report. J Gynecol Oncol 2008, 19: 275–278. 10.3802/jgo.2008.19.4.275PubMed CentralView ArticlePubMedGoogle Scholar
- Peterson WF: Malignant degeneration of benign cystic teratomas of the overy; a collective review of the literature. Obstet Gynecol Surv 1957, 12: 793–830. 10.1097/00006254-195712000-00001View ArticlePubMedGoogle Scholar
- Nor Azlin MI, Isa MR, Zaleha AM: Bilateral ovarian teratoma with squamous cell malignancy in a young woman: a diagnostic and management challenge. Int Med J 2005, 4: 51–53.Google Scholar
- Ueda G, Fujita M, Ogawa H, Sawada M, Inoue M, Tanizawa O: Adenocarcinoma in a benign cystic teratoma of the ovary: report of a case with a long survival period. Gynecol Oncol 1993, 48: 259–263. 10.1006/gyno.1993.1044View ArticlePubMedGoogle Scholar
- Kajo K, Masák L, Sorkovská D, Vallová M, Kajo M, Macháleková K, He’pianská L: Mucinous carcinoma (non-intestinal type) arising in the ovarian mature cystic teratoma - a case report. Cesk Patol 2013, 49: 141–145.PubMedGoogle Scholar
- Min KJ, Jee BC, Lee HS, Kim YB: Intestinal adenocarcinoma arising in a mature cystic teratoma of the ovary: a case report. Pathol Res Pract 2006, 202: 531–535. 10.1016/j.prp.2006.03.005View ArticlePubMedGoogle Scholar
- Takai M, Kanemura M, Kawaguchi H, Fujiwara S, Yoo S, Tanaka Y, Tsunetoh S, Terai Y, Yamada T, Ohmichi M: Mucinous adenocarcinoma of the intestinal type arising from mature cystic teratoma of the ovary: a rare case report and review of the literature. J Ovarian Res 2012, 5: 41–46. 10.1186/1757-2215-5-41PubMed CentralView ArticlePubMedGoogle Scholar
- Vang R, Gown AM, Zhao C, Barry TS, Isacson C, Richardson MS, Ronnett BM: Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 2007, 31: 854–869. 10.1097/PAS.0b013e31802efb45View ArticlePubMedGoogle Scholar
- Tol J, Punt CJ: Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010, 32: 437–453. 10.1016/j.clinthera.2010.03.012View ArticlePubMedGoogle Scholar
- Yeung Y, Tebbutt NC: Bevacizumab in colorectal cancer: current and future directions. Expert Rev Anticancer Ther 2012, 12: 1263–1273. 10.1586/era.12.104View ArticlePubMedGoogle Scholar
- Liévre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66: 3992–3995. 10.1158/0008-5472.CAN-06-0191View ArticlePubMedGoogle Scholar
- Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A: Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009, 35: 262–271. 10.1016/j.ctrv.2008.11.005View ArticlePubMedGoogle Scholar
- Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol 2010, 28: 466–474. 10.1200/JCO.2009.23.3452View ArticlePubMedGoogle Scholar
- Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J: BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients’ outcome. PLoS One 2013, 8: e84604. 10.1371/journal.pone.0084604PubMed CentralView ArticlePubMedGoogle Scholar
- Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B: BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006, 5: 2. 10.1186/1476-4598-5-2View ArticlePubMedGoogle Scholar
- Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, Kuo CH, Wu DC, Chai CY, Wang JY: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer 2013, 13: 599. 10.1186/1471-2407-13-599PubMed CentralView ArticlePubMedGoogle Scholar
- Fishman A, Edelstein E, Altaras M, Beyth Y, Bernheim J: Adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary. Gynecol Oncol 1998, 70: 418–420. 10.1006/gyno.1998.5123View ArticlePubMedGoogle Scholar
- Kushima M: Adenocarcinoma arising from mature cystic teratoma of the ovary. Pathol Int 2004, 54: 139–143. 10.1111/j.1440-1827.2004.01599.xView ArticlePubMedGoogle Scholar
- Levine DA, Villella JA, Poynor EA, Soslow RA: Gastrointestinal adenocarcinoma arising in a mature cystic teratoma of the ovary. Gynecol Oncol 2004, 94: 597–599. 10.1016/j.ygyno.2004.05.045View ArticlePubMedGoogle Scholar
- Stojsic J, Kontic M, Subotic D, Popovic M, Tomasevic D, Lukic J: Intestinal type of lung adenocarcinoma in younger adults. Case Rep Pulmonol 2014, 2014: 282196.PubMed CentralPubMedGoogle Scholar
- Hershkovitz D, Vlodavsky E, Simon E, Ben-Izhak O: KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature. Pathol Int 2013, 63: 611–614. 10.1111/pin.12123View ArticlePubMedGoogle Scholar
- Chang JL, Liu KY, Kuo YL, Lee WH: Adenocarcinoma arising from mature cystic teratoma of the ovary. J Med Sci 2002, 22: 239–244.Google Scholar
- Cymbaluk-Ploska A, Chudecka-Głaz A, Chosia M, Ashuryk O, Menkiszak J: Conservative treatment of a young patient with thyroid carcinoma in adult ovarian teratoma - case report. Gynecol Endocrinol 2014, 30: 187–191. 10.3109/09513590.2013.860122View ArticlePubMedGoogle Scholar
- Sun K, You Q, Zhao M, Yao H, Xiang H, Wang L: Concurrent priomary carcinoid tumor arising within mature teratoma and clear cell renal cell carcinoma in the horseshoe kidney: report of a rare case and review of the literature. Int J Clin Exp Pathol 2013, 6: 2578–2584.PubMed CentralPubMedGoogle Scholar
- Hinshaw HD, Smith AL, Desouki MM, Olawaiye AB: Malignant transformation of a mature cystic ovarian teratoma into thyroid carcinoma, mucinous adenocarcinoma, and strumal carcinoid: a case report and literature review. Case Rep Obstet Gynecol 2012, 2012: 269489.PubMed CentralPubMedGoogle Scholar
- Guney M, Oral B, Demir F, Ozsoy M, Kapucuoglu N: Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary–case report. Eur J Gynaecol Oncol 2006, 27: 304–306.PubMedGoogle Scholar
- Kerr SE, Flotte AB, McFalls MJ, Vrana JA, Halling KC, Bell DA: Matching maternal isodisomy in mucinous carcinomas and associated ovarian teratomas provides evidence of germ cell derivation for some mucinous ovarian tumors. Am J Surg Pathol 2013, 37: 1229–1235. 10.1097/PAS.0b013e31828f9ecbView ArticlePubMedGoogle Scholar
- Fujii K, Yamashita Y, Yamamoto T, Takahashi K, Hashimoto K, Miyata T, Kawai K, Kikkawa F, Toyokuni S, Nagasaka T: Ovarian mucinous tumors arising from mature cystic teratomas-a molecular genetic approach for understanding the cellular origin. Hum Pathol 2014, 45: 717–724. 10.1016/j.humpath.2013.10.031View ArticlePubMedGoogle Scholar
- Sakuma M, Otsuki T, Yoshinaga K, Utsunomiya H, Nagase S, Takano T, Niikura H, Ito K, Otomo K, Tase T, Watanabe Y, Yaegashi N: Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases. Int J Gynecol Cancer 2010, 20: 766–771. 10.1111/IGC.0b013e3181daaf1dView ArticlePubMedGoogle Scholar
- Arora DS, Haldane S: Carcinosarcoma arising in a dermoid cyst of the ovary. J Clin Pathol 1996, 49: 519–521. 10.1136/jcp.49.6.519PubMed CentralView ArticlePubMedGoogle Scholar
- Dechaphunkul A, Bigras G, Sawyer M: Response to 5-Fluorouracil-based chemotherapy in a patient with metastatic colonic-type adenocarcinoma arising in a primary mediastinal teratoma. Case Rep Oncol Med 2012, 2012: 729278.PubMed CentralPubMedGoogle Scholar
- Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9: 962–972. 10.1016/S1470-2045(08)70206-7View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.